Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
2.760
0.00 (0.00%)
At close: Jun 16, 2025, 4:00 PM
2.830
+0.070 (2.54%)
After-hours: Jun 16, 2025, 6:24 PM EDT
Mereo BioPharma Group Stock Forecast
Stock Price Forecast
The 7 analysts that cover Mereo BioPharma Group stock have a consensus rating of "Strong Buy" and an average price target of $7.71, which forecasts a 179.35% increase in the stock price over the next year. The lowest target is $7 and the highest is $10.
Price Target: $7.71 (+179.35%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 13, 2025.
Analyst Ratings
The average analyst rating for Mereo BioPharma Group stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +153.62% | May 13, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +153.62% | Apr 9, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $7 | Buy | Initiates | $7 | +153.62% | Mar 27, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +153.62% | Mar 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +153.62% | Mar 18, 2025 |
Financial Forecast
Revenue This Year
23.67M
Revenue Next Year
36.46M
from 23.67M
Increased by 54.07%
EPS This Year
-0.05
from -0.29
EPS Next Year
-0.02
from -0.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 101.0M | 75.8M | 109.7M | ||
| Avg | 23.7M | 36.5M | 65.4M | ||
| Low | n/a | 988,751 | 18.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 220.2% | 200.8% | ||
| Avg | - | 54.1% | 79.5% | ||
| Low | - | -95.8% | -49.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.02 | 0.06 | 0.02 | ||
| Avg | -0.05 | -0.02 | -0.03 | ||
| Low | -0.07 | -0.07 | -0.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.